RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Innovent Biologics Stock

Innovent Biologics EBIT 2024

Innovent Biologics EBIT

-1.08 B CNY

Ticker

1801.HK

ISIN

KYG4818G1010

WKN

A2N7N8

In 2024, Innovent Biologics's EBIT was -1.08 B CNY, a -26.72% increase from the -1.47 B CNY EBIT recorded in the previous year.

The Innovent Biologics EBIT history

YEAREBIT (undefined CNY)
2029e8.08
2028e6.18
2027e3.97
2026e1.54
2025e0.04
2024e-1.08
2023-1.47
2022-3.02
2021-2.66
2020-0.43
2019-1.78
2018-1.5
2017-0.62
2016-0.41

Innovent Biologics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Innovent Biologics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Innovent Biologics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Innovent Biologics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Innovent Biologics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Innovent Biologics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Innovent Biologics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Innovent Biologics’s growth potential.

Innovent Biologics Revenue, EBIT and net profit per share

DateInnovent Biologics RevenueInnovent Biologics EBITInnovent Biologics Net Income
2029e24.9 B undefined8.08 B undefined5.11 B undefined
2028e21.6 B undefined6.18 B undefined4.61 B undefined
2027e18.34 B undefined3.97 B undefined4.4 B undefined
2026e13.6 B undefined1.54 B undefined1.56 B undefined
2025e10.56 B undefined41.92 M undefined139.79 M undefined
2024e8.13 B undefined-1.08 B undefined-774.52 M undefined
20236.21 B undefined-1.47 B undefined-1.03 B undefined
20224.56 B undefined-3.02 B undefined-2.18 B undefined
20214.27 B undefined-2.66 B undefined-2.73 B undefined
20203.84 B undefined-426.5 M undefined-998.42 M undefined
20191.05 B undefined-1.78 B undefined-1.72 B undefined
20189.48 M undefined-1.5 B undefined-5.77 B undefined
201718.54 M undefined-624.73 M undefined-562.32 M undefined
20160 undefined-413.27 M undefined-504.2 M undefined

Innovent Biologics stock margins

The Innovent Biologics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Innovent Biologics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Innovent Biologics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Innovent Biologics's sales revenue. A higher gross margin percentage indicates that the Innovent Biologics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Innovent Biologics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Innovent Biologics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Innovent Biologics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Innovent Biologics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Innovent Biologics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Innovent Biologics Margin History

Innovent Biologics Gross marginInnovent Biologics Profit marginInnovent Biologics EBIT marginInnovent Biologics Profit margin
2029e81.69 %32.47 %20.51 %
2028e81.69 %28.6 %21.33 %
2027e81.69 %21.66 %24.01 %
2026e81.69 %11.35 %11.46 %
2025e81.69 %0.4 %1.32 %
2024e81.69 %-13.28 %-9.52 %
202381.69 %-23.75 %-16.56 %
202279.57 %-66.18 %-47.83 %
202188.16 %-62.22 %-63.91 %
202089.91 %-11.1 %-25.97 %
201988.08 %-169.76 %-164.19 %
201881.69 %-15,779.4 %-60,899.99 %
201781.69 %-3,369.99 %-3,033.33 %
201681.69 %0 %0 %

Innovent Biologics Aktienanalyse

What does Innovent Biologics do?

Innovent Biologics Inc. is an innovative biopharmaceutical company that focuses on the discovery, development, and commercialization of world-leading biological therapies. The company was founded in 2011 by a group of outstanding scientists who already had extensive experience in biological research and development. Since then, Innovent Biologics Inc. has achieved many successes and has become a significant player in the biopharmaceutical industry. Innovent Biologics' business model is based on the use of cutting-edge technology and collaboration with partners to develop and bring innovative biopharmaceuticals to the market. The company utilizes a platform technology based on a combination of protein production and antibody development to provide a strong foundation for its innovative pipeline of therapeutics. Innovent Biologics specializes in three main areas: cancer therapy, autoimmune diseases, and ophthalmology. The company has developed an impressive number of product candidates to meet the need for innovative therapeutics in these areas. In the field of cancer therapy, Innovent Biologics specializes particularly in the treatment of lung tumors. The company has successfully developed tyrosine kinase inhibitors targeting important therapy targets. Additionally, the company has also developed antibodies against cancer that stimulate the patient's immune system to fight tumor cells. Innovent Biologics is also a leader in the development of drugs for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. By identifying highly specific antibodies with therapeutic potential, the company has developed a pipeline of promising drug candidates. In the field of ophthalmology, Innovent Biologics has achieved remarkable successes. The company has developed an innovative therapeutic antibody platform specifically targeting the treatment of eye diseases. This platform allows for the optimization of the drug to better suit the eye and achieve higher efficacy. Innovent Biologics has already discovered several antibody candidates that have produced promising clinical results. In addition to its product candidates, Innovent Biologics has also formed partnerships with other industry players. The company collaborates closely with other biopharmaceutical companies to jointly develop and market innovative therapeutics. Overall, Innovent Biologics Inc. has built an impressive track record and experience in a relatively short period. It is a leading player in the development of biopharmaceuticals that have the potential to revolutionize the healthcare industry. The company has a strong pipeline of product candidates in various therapy areas, supported by innovative platform technology. Innovent Biologics is able to further expand its work through close collaboration with partners and a variety of collaborators. Innovent Biologics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Innovent Biologics's EBIT

Innovent Biologics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Innovent Biologics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Innovent Biologics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Innovent Biologics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Innovent Biologics stock

How much did Innovent Biologics achieve in EBIT for the current year?

In the current year, Innovent Biologics has achieved an EBIT of -1.08 B CNY.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Innovent Biologics.

How has the EBIT of Innovent Biologics developed in recent years?

The EBIT of Innovent Biologics has increased by -26.725% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Innovent Biologics?

The EBIT of Innovent Biologics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Innovent Biologics pay?

Over the past 12 months, Innovent Biologics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Innovent Biologics is expected to pay a dividend of 0 CNY.

What is the dividend yield of Innovent Biologics?

The current dividend yield of Innovent Biologics is .

When does Innovent Biologics pay dividends?

Innovent Biologics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Innovent Biologics?

Innovent Biologics paid dividends every year for the past 0 years.

What is the dividend of Innovent Biologics?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Innovent Biologics located?

Innovent Biologics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Innovent Biologics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Innovent Biologics from 12/26/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 12/26/2024.

When did Innovent Biologics pay the last dividend?

The last dividend was paid out on 12/26/2024.

What was the dividend of Innovent Biologics in the year 2023?

In the year 2023, Innovent Biologics distributed 0 CNY as dividends.

In which currency does Innovent Biologics pay out the dividend?

The dividends of Innovent Biologics are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Innovent Biologics

Our stock analysis for Innovent Biologics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innovent Biologics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.